Skip to content

Propofol Versus Sevoflurane for Induction of GA in Infants

The Hemodynamic Effects of Propofol Versus Sevoflurane for Induction of Anesthesia in Healthy Infants as Measured by Electrical Cardiometry: Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05105022
Enrollment
122
Registered
2021-11-03
Start date
2021-10-01
Completion date
2024-01-01
Last updated
2023-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Induction of General Anesthesia

Brief summary

This comparative study aims to investigate the haemodynamic safety profile for induction of general anesthesia in infants 3 months or less guided by electrical cardiometry parameters versus sevoflurane.

Detailed description

This study aims to investigate the hemodynamic effects of both propofol and sevoflurane for induction of anesthesia in infants less than 3 months of age by electrical cardiometry. The investigators hypothesized that propofol will have a safe hemodynamic profile for induction of anesthesia in infants less than 3 months of age as measured by electrical cardiometry in addition to its favorable pharmacokinetic profile of rapid induction and optimal intubation conditions.It is conducted at Abu Al Reesh Children's Hospital, Faculty of Medicine, Cairo University based on an institutional protocol used as a standard of care to induce anesthesia

Interventions

DRUGPropofol

Intravenous induction of general anesthesia in infants 3 months or less.

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
1 Days to 90 Days
Healthy volunteers
No

Inclusion criteria

* infants aged 3 months or less scheduled for elective surgery

Exclusion criteria

* significant structural congenital heart disease * intracranial malformation. * preexisting hemodynamic instability. * history of seizures, opioids, and/or hypnotic administration. * prematurity (defined as gestational age \<37 weeks)

Design outcomes

Primary

MeasureTime frameDescription
cardiac index15 minutesL/min/m2

Secondary

MeasureTime frameDescription
MAP15 minutesmmHg

Countries

Egypt

Contacts

Primary ContactShymaa Fathy, MD
angel6122003@yahoo.com+201000455897

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026